Glioblastoma and other primary brain malignancies in adults: a review
Importance Malignant primary brain tumors cause more than 15 000 deaths per year in the
United States. The annual incidence of primary malignant brain tumors is approximately 7 …
United States. The annual incidence of primary malignant brain tumors is approximately 7 …
NF‐κB signaling in inflammation and cancer
T Zhang, C Ma, Z Zhang, H Zhang, H Hu - MedComm, 2021 - Wiley Online Library
Since nuclear factor of κ‐light chain of enhancer‐activated B cells (NF‐κB) was discovered
in 1986, extraordinary efforts have been made to understand the function and regulating …
in 1986, extraordinary efforts have been made to understand the function and regulating …
Genetics and pathogenesis of diffuse large B-cell lymphoma
R Schmitz, GW Wright, DW Huang… - New England journal …, 2018 - Mass Medical Soc
Background Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B …
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B …
A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications
GW Wright, JD Phelan, ZA Coulibaly, S Roulland… - Cancer cell, 2020 - cell.com
The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …
Role of Bruton's tyrosine kinase in B cells and malignancies
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …
signaling that is critical for proliferation and survival of leukemic cells in many B cell …
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
A Alu, H Lei, X Han, Y Wei, X Wei - Journal of Hematology & Oncology, 2022 - Springer
Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances
T Wen, J Wang, Y Shi, H Qian, P Liu - Leukemia, 2021 - nature.com
Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …
A multiprotein supercomplex controlling oncogenic signalling in lymphoma
B cell receptor (BCR) signalling has emerged as a therapeutic target in B cell lymphomas,
but inhibiting this pathway in diffuse large B cell lymphoma (DLBCL) has benefited only a …
but inhibiting this pathway in diffuse large B cell lymphoma (DLBCL) has benefited only a …
Primary central nervous system lymphoma
LR Schaff, C Grommes - Blood, The Journal of the American …, 2022 - ashpublications.org
Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphomatous
malignancy that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without …
malignancy that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without …
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Y Song, K Zhou, D Zou, J Zhou, J Hu… - Blood, The Journal …, 2022 - ashpublications.org
Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed/refractory
(R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, is …
(R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, is …